| Autor: |
Christoph, Wetz, I, Apostolova, I G, Steffen, F, Hofheinz, C, Furth, D, Kupitz, J, Ruf, M, Venerito, S, Klose, Holger, Amthauer |
| Rok vydání: |
2016 |
| Předmět: |
|
| Zdroj: |
Molecular imaging and biology. 19(3) |
| ISSN: |
1860-2002 |
| Popis: |
The purpose of this study was to assess the value of the spatial heterogeneity of somatostatin receptor (SSR) volume, quantified as asphericity (ASP), and to predict response to peptide receptor radionuclide therapy (PRRT) in patients with metastatic gastroenteropancreatic neuroendocrine neoplasms (GEP-NEN).From June 2011 to May 2013, patients suffering from GEP-NEN who underwent pretherapeutic [Seventy-seven metastases (liver, n = 40; lymph node, n = 24; bone, n = 11; pancreas, n = 2) showed SSR expression. A higher ASP level was significantly associated with poorer response at both time points. ROC analyses revealed the highest area under the curve (AUC) for discrimination between RL and NRL for ASP after 4 months (AUC 0.97; p = 0.019) and after 12 months (AUC 0.96; p 0.001), followed by the Krenning score (AUC 0.74; p = 0.082 and AUC 0.85; p 0.001, respectively) and M/L ratio (AUC 0.77; p = 0.107 and AUC 0.82; p 0.001). The optimal cutoff value for ASP was 5.12 % (sensitivity, 90 %; specificity, 93 %).Asphericity of SSR-expressing lesions in pretherapeutic single-photon emission computed tomography with integrated computed tomography (SPECT/CT) is a promising parameter for predicting response to PRRT in gastroenteropancreatic neuroendocrine neoplasms. |
| Databáze: |
OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink